Tim-3 expression and its role in hepatocellular carcinoma

被引：107

作者：

Liu, Feifei ^{[1
]}

Liu, Yanning ^{[1
]}

Chen, Zhi ^{[1
]}

机构：

[1] Zhejiang Univ, State Key Lab Diag & Treatment Infect Dis, Affiliated Hosp 1, Coll Med,Collaborat Innovat Ctr Diag & Treatment, 79 Qingchun Rd,6A-17, Hangzhou 310003, Zhejiang, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2018年 / 11卷

关键词：

Hepatocellular carcinoma; Tim-3; Immune checkpoint blockade; Immunotherapy; T-CELL IMMUNOGLOBULIN; EPITHELIAL-MESENCHYMAL TRANSITION; OLIGONUCLEOTIDE APTAMER; ANTITUMOR IMMUNITY; PD-1; BLOCKADE; UP-REGULATION; CANCER; RECEPTOR; THERAPY; MUCIN-3;

D O I：

10.1186/s13045-018-0667-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma (HCC) is one of the most common tumors in the world, and its mortality is still on the rise. Limited treatments and low chemotherapy sensitivity of HCC make new therapeutic strategies urgently needed. With the rise of immune checkpoint blockade, anti-CTLA-4 antibodies and anti-PD-1 antibodies have shown therapeutic effects in various tumors. T cell immunoglobulin mucin-3 (Tim-3), a newly discovered immune checkpoint molecule, plays a major role in the development of HCC. Tim-3 can be used to evaluate the prognosis and therapeutic effects in HCC, and Tim-3 intervention has shown anti-tumor effects in preclinical experiments. This review summarizes findings regarding Tim-3 and HCC in recent years and discusses the rationale of Tim-3 as a therapeutic target for HCC.

引用

页数：12

共 50 条

[31] The role of TIM-3 in sepsis: a promising target for immunotherapy?
Wang, Changli
Liu, Jinhai
Wu, Qi
Wang, Zhi
Hu, Baoji
Bo, Lulong
FRONTIERS IN IMMUNOLOGY, 2024, 15
[32] The role of tim-3 polymorphisms in idiopathic thrombocytopenic purpura
Du, W.
Wang, D.
Zhao, H.
Xu, J.
Gu, D.
Xue, F.
Ge, J.
Yang, R.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 867 - 867
[33] Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma
Chen Cai
Yi-Fan Xu
Zhen-Jie Wu
Qin Dong
Min-Yu Li
Jason C. Olson
Yaron M. Rabinowitz
Lin-Hui Wang
Yinghao Sun
World Journal of Urology, 2016, 34 : 561 - 567
[34] EXPRESSION AND CORRELATION OF PD-1 AND TIM-3 IN PATIENTS WITH ORAL SQUAMOUS CELL CARCINOMA
Li, Liping
Li, Lihong
Lin, Wu
ACTA MEDICA MEDITERRANEA, 2021, 37 (02): : 1069 - 1074
[35] TIM-3 polymorphism is involved in the progression of esophageal squamous cell carcinoma by regulating gene expression
Cui, Sai-Jin
Li, Yan
Zhou, Rong-Miao
Liu, Lu
Cao, Shi-Ru
Huang, Xi
Huo, Xiang-Ran
Wang, Na
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2021, 62 (04) : 273 - 283
[36] Distinct role of Tim-3 in systemic lupus erythematosus and clear cell renal cell carcinoma
Zheng, Hongying
Guo, Xingqing
Tian, Qingwu
Li, Hui
Zhu, Yuanqi
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (05): : 7029 - 7038
[37] Neoantigen Immunotherapeutic-Gel Combined with TIM-3 Blockade Effectively Restrains Orthotopic Hepatocellular Carcinoma Progression
Zhao, Qingfu
Wang, Yunhao
Zhao, Binyu
Chen, Hengkai
Cai, Zhixiong
Zheng, Youshi
Zeng, Yongyi
Zhang, Da
Liu, Xiaolong
NANO LETTERS, 2022, 22 (05) : 2048 - 2058
[38] Tim-3 expression in glioma cells is associated with drug resistance
Zhang, Ji
Zhu, Zheng Quan
Li, Yan Xia
Zhuang, Qiu Feng
Lai, Yuanhong
Li, Shao Fang
Xu, Xiao Bing
Liu, Jian Min
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2019, 15 (04) : 882 - 888
[39] NK cell expression of Tim-3: First impressions matter
So, Edward C.
Khaladj-Ghom, Ariana
Ji, Yaping
Amin, Julian
Song, Yang
Burch, Erin
Zhou, Hua
Sun, Haoping
Chen, Shaodong
Bentzen, Soren
Hertzano, Ronna
Zhang, Xiaoyu
Strome, Scott E.
IMMUNOBIOLOGY, 2019, 224 (03) : 362 - 370
[40] Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma
Su, Hang
Xie, Huikang
Dai, Chenyang
Ren, Yijiu
She, Yunlang
Xu, Long
Chen, Donglai
Xie, Dong
Zhang, Liping
Jiang, Gening
Chen, Chang
LUNG CANCER, 2018, 121 : 18 - 24

← 1 2 3 4 5 →